Drug intelligence / Profile preview

TEGs

Development stage: Unknown
Lead developer: Century Therapeutics
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies

Overview

TEGs (αβT cells engineered to express a defined γδTCR) are a novel class of engineered immune cells developed by Gadeta for cancer immunotherapy. These cells are designed to recognize and eliminate cancer cells, including multiple myeloma cells, through the expression of tumor-specific Vγ9Vδ2 T cell receptors. The mechanism involves an inside-out killing response that engages Butyrophilin subfamily 3 member A1 (CD277). TEGs are being advanced into clinical trials for acute myeloid leukemia and are also being investigated for multiple myeloma.

Other names: αβT cells engineered to express a defined γδTCR

Targets

BTN3A1 (Butyrophilin 3A1/2A1 complex)

Beyond the preview

Go deeper on TEGs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TEGs.

Explore the full profile